AMPH Q3 2021 Earnings — Amphastar Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AMPHAmphastar Pharmaceuticals, Inc.

$860M

Q3 2021 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$112M+34.5% YoY

Gross Profit

$51M45.6% margin

Operating Income

$25M22.1% margin

Net Income

$30M26.3% margin

EPS (Diluted)

$0.59

QoQ Revenue Growth

+10.4%

Cash Flow

Operating Cash Flow

$3M

Free Cash Flow

-$5M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$652M

Total Liabilities

$222M

Stockholders' Equity

$430M

Cash & Equivalents

$107M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$112M	$83M	+34.5%
Gross Profit	$51M	$37M	+40.2%
Operating Income	$25M	$4M	+604.3%
Net Income	$30M	$4M	+654.0%

Revenue Segments

Finished Pharmaceutical Products Segment

$109M97%

Active Pharmaceutical Ingredient Segment

$3M3%